Sarepta Therapeutics Inc $ 88.05 2.35 (2.74%)
Volume:
914,488
Avg Vol (1m):
1,710,079
Market Cap $:
6.55 Bil
Enterprise Value $:
5.92 Bil
P/E (TTM):
0.00
P/B:
5.91
| Earnings Power Value | ||
| Net Current Asset Value | ||
| Tangible Book | ||
| Projected FCF | ||
| Median P/S Value | ||
|
Price: $88.05 | ||
Manual of Stocks™ Web
Financial Strength | 5/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Cash-To-Debt | 2.29 | ||
| Equity-to-Asset | 0.63 | ||
| Debt-to-Equity | 0.44 | ||
| Debt-to-EBITDA | -0.93 | ||
| Piotroski F-Score | 3 | ||
| Altman Z-Score | 4.24 | ||
| Beneish M-Score | -1.86 | ||
| WACC vs ROIC | |||
Profitability | 3/10 |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Operating Margin % | -162.87 | ||
| Net Margin % | -165.52 | ||
| ROE % | -59.18 | ||
| ROA % | -36.64 | ||
| ROC (Joel Greenblatt) % | -257.54 | ||
| 3-Year Revenue Growth Rate | 433.1 | ||
| 3-Year EBITDA Growth Rate | 1.8 | ||
| 3-Year EPS without NRI Growth Rate | -1.6 |
Ratios |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| PB Ratio | 5.91 | ||
| PS Ratio | 17.96 | ||
| EV-to-EBIT | -11.03 | ||
| EV-to-EBITDA | -11.46 | ||
| EV-to-Revenue | 17.21 | ||
| Current Ratio | 8.81 | ||
| Quick Ratio | 7.84 | ||
| Days Inventory | 940.61 | ||
| Days Sales Outstanding | 59.52 | ||
| Days Payable | 322.44 |
Dividend & Buy Back |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -17 |
Valuation & Return |
| Current | Vs Industry | Vs History | |
|---|---|---|---|
| Price-to-Tangible-Book | 5.99 | ||
| Price-to-Median-PS-Value | 0.68 | ||
| Earnings Yield (Greenblatt) % | -9.11 |